Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

Molecular Cancer Therapeutics
Tristan M SissungAlex Sparreboom

Abstract

Using a single nucleotide polymorphism association study in 52 men with prostate cancer receiving docetaxel, we found that individuals carrying two copies of the CYP1B1*3 polymorphic variant had a poor prognosis after docetaxel-based therapies compared with individuals carrying at least one copy of the CYP1B1*1 allele (30.6 versus 12.8 months; P=0.0004). The association between CYP1B1*3 and response to therapy was not observed in similar subjects receiving non-taxane-based therapy (P=0.18). The systemic clearance of docetaxel was also unrelated to CYP1B1 genotype status (P=0.39), indicating that the association of CYP1B1*3 with clinical response is not due to docetaxel metabolism. To explain these results, we hypothesized that an indirect gene-drug interaction was interfering with the primary mechanism of action of docetaxel, tubulin polymerization. We therefore conducted tubulin polymerization experiments with taxanes in the presence or absence of certain CYP1B1 estrogen metabolites, which are known to bind to nucleophilic sites in proteins and DNA, that revealed the primary estrogen metabolite of CYP1B1, 4-hydroxyestradiol (4-OHE2), when oxidized to estradiol-3,4-quinone strongly inhibits tubulin polymerization. The 4-OHE2 is...Continue Reading

References

Oct 1, 1991·Protein Expression and Purification·D L SackettJ Wolff
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoE Hamel
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·J D Yager, J G Liehr
Oct 1, 1996·Protein Science : a Publication of the Protein Society·J WolffL Knipling
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N A DawsonC E Myers
Jun 6, 1997·Journal of Chromatography. B, Biomedical Sciences and Applications·W J LoosA Sparreboom
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BrunoL B Sheiner
Nov 2, 1999·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·M C McFadyenG I Murray
Aug 30, 2000·Journal of the National Cancer Institute. Monographs·M C Bosland
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M LouwerensR de Wit
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bruno Bournique, Audrey Lemarié
Jan 31, 2004·International Journal of Radiation Oncology, Biology, Physics·Dawn M CarnellSteven A Everett
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William L DahutWilliam D Figg
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Jan 15, 2005·Annals of the New York Academy of Sciences·Ercole L Cavalieri, Eleanor G Rogan
Jan 17, 2007·The Pharmacogenomics Journal·S MarshT W Synold

❮ Previous
Next ❯

Citations

Jul 16, 2010·Breast Cancer Research and Treatment·Roberta RizzoAlessandra Ferlini
Apr 25, 2012·Breast Cancer Research and Treatment·Daniel L HertzE Claire Dees
Dec 4, 2013·Nature Reviews. Urology·Rosalind EelesZsofia Kote-Jarai
Dec 15, 2010·Pharmacogenetics and Genomics·Connie OshiroRuss Altman
Feb 23, 2011·The Oncologist·Rahul Aggarwal, Charles J Ryan
Jul 11, 2013·Pharmacogenomics·Daniel L Hertz
Apr 5, 2014·BioMed Research International·Thomas Van den BroeckFrank Claessens
Apr 21, 2012·Pharmacogenomics·Anna González-Neira
Jan 24, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yi LiuChang-chun Fan
Apr 14, 2010·Expert Opinion on Investigational Drugs·Raffaele LongoGiampietro Gasparini
May 9, 2012·Cancer Letters·Ketan GajjarFrancis L Martin
Sep 16, 2010·Fundamental & Clinical Pharmacology·Pauline Gerritsen-van SchieveenUNKNOWN Therapeutic drug monitoring group of the French Society of Pharmacology and Therapeutics
Aug 25, 2015·Cancer Chemotherapy and Pharmacology·Jai N Patel, Apostolos Papachristos
Dec 17, 2014·Journal of Cancer Research and Clinical Oncology·Enrico VasileElisa Giovannetti
Sep 10, 2014·Biochimica Et Biophysica Acta·Tristan M SissungRomano Danesi
Dec 6, 2014·Molecular Genetics and Genomics : MGG·Jie-Ying LiuWei Wang
Aug 12, 2010·Thérapie·Pauline Gerritsen-van SchieveenUNKNOWN Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Dec 19, 2019·Pharmacogenomics·Eric JohnsonUmang Swami
Jun 23, 2020·British Journal of Cancer·Valérie Le MorvanJacques Robert
Dec 11, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Zlatko Dembic
Jan 24, 2021·Archives of Pharmacal Research·Yeo-Jung KwonYoung-Jin Chun
Jan 6, 2021·Oncotarget·Randa El-ZeinSherif Z Abdel-Rahman
Apr 9, 2021·British Journal of Cancer·Jean-Philippe EmondEric Lévesque
Jun 28, 2011·Clinical Genitourinary Cancer·Motofumi SuzukiTadaichi Kitamura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.